| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma C Robert, L Thomas, I Bondarenko, S O'Day, J Weber, C Garbe, C Lebbe, ... New England Journal of Medicine 364 (26), 2517-2526, 2011 | 5446 | 2011 |
| Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor H Ikeda, B Lethé, F Lehmann, N Van Baren, JF Baurain, C De Smet, ... Immunity 6 (2), 199-208, 1997 | 923 | 1997 |
| Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 MJ van den Bent, AA Brandes, R Rampling, MCM Kouwenhoven, JM Kros, ... Journal of Clinical Oncology 27 (8), 1268, 2009 | 641 | 2009 |
| Overall survival benefit with tebentafusp in metastatic uveal melanoma P Nathan, JC Hassel, P Rutkowski, JF Baurain, MO Butler, M Schlaak, ... New England Journal of Medicine 385 (13), 1196-1206, 2021 | 549 | 2021 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The lancet oncology 22 (5), 643-654, 2021 | 309 | 2021 |
| Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma B Neyns, J Sadones, E Joosens, F Bouttens, L Verbeke, JF Baurain, ... Annals of Oncology 20 (9), 1596-1603, 2009 | 286 | 2009 |
| Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm … RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, ... The Lancet Oncology 22 (5), 609-619, 2021 | 248 | 2021 |
| Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases A Cipponi, M Mercier, T Seremet, JF Baurain, I Théate, J van den Oord, ... Cancer research 72 (16), 3997-4007, 2012 | 244 | 2012 |
| Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study JP Machiels, L Duck, B Honhon, B Coster, JC Coche, P Scalliet, ... Annals of oncology 16 (12), 1898-1905, 2005 | 186 | 2005 |
| Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) A Marabelle, R Andtbacka, K Harrington, I Melero, R Leidner, T de Baere, ... Annals of Oncology 29 (11), 2163-2174, 2018 | 168 | 2018 |
| A Point Mutation in the α-Actinin-4 Gene Generates an Antigenic Peptide Recognized by Autologous Cytolytic T Lymphocytes on a Human Lung Carcinoma H Echchakir, F Mami-Chouaib, I Vergnon, JF Baurain, V Karanikas, ... Cancer research 61 (10), 4078-4083, 2001 | 163 | 2001 |
| Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials GV Long, JS Weber, J Larkin, V Atkinson, JJ Grob, D Schadendorf, ... JAMA oncology 3 (11), 1511-1519, 2017 | 160 | 2017 |
| High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long … V Karanikas, D Colau, JF Baurain, R Chiari, J Thonnard, ... Cancer research 61 (9), 3718-3724, 2001 | 160 | 2001 |
| Role of PET in the Initial Staging of Cutaneous Malignant Melanoma: Systematic Review1 B Krug, R Crott, M Lonneux, JF Baurain, AS Pirson, T Vander Borght Radiology 249 (3), 836-844, 2008 | 154 | 2008 |
| Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma? BJ Van den Eynde, N van Baren, JF Baurain Annual Review of Cancer Biology 4, 241-256, 2020 | 141 | 2020 |
| Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial S Leyvraz, S Piperno-Neumann, S Suciu, JF Baurain, M Zdzienicki, ... Annals of oncology 25 (3), 742-746, 2014 | 135 | 2014 |
| High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene JF Baurain, D Colau, N van Baren, C Landry, V Martelange, M Vikkula, ... The Journal of Immunology 164 (11), 6057-6066, 2000 | 131 | 2000 |
| A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer EL Mayer, JF Baurain, J Sparano, L Strauss, M Campone, P Fumoleau, ... Clinical cancer research 17 (21), 6897-6904, 2011 | 123 | 2011 |
| Availability of digital dermoscopy in daily practice dramatically reduces the number of excised melanocytic lesions: results from an observational study I Tromme, L Sacré, F Hammouch, C Legrand, L Marot, P Vereecken, ... British Journal of Dermatology 167 (4), 778-786, 2012 | 114 | 2012 |
| Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene R Chiari, F Foury, E De Plaen, JF Baurain, J Thonnard, P G. Coulie Cancer research 59 (22), 5785-5792, 1999 | 114 | 1999 |
